Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) EBT (2023 - 2025)

Historic EBT for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$35.3 million.

  • Inhibrx Biosciences' EBT rose 1962.43% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.1 million, marking a year-over-year decrease of 10943.64%. This contributed to the annual value of $1.7 billion for FY2024, which is 80396.54% up from last year.
  • As of Q3 2025, Inhibrx Biosciences' EBT stood at -$35.3 million, which was up 1962.43% from -$28.7 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' EBT ranged from a high of $1.9 billion in Q2 2024 and a low of -$92.0 million during Q4 2023
  • Moreover, its 3-year median value for EBT was -$45.5 million (2023), whereas its average is $139.0 million.
  • Per our database at Business Quant, Inhibrx Biosciences' EBT surged by 404926.99% in 2024 and then crashed by 10154.21% in 2025.
  • Inhibrx Biosciences' EBT (Quarter) stood at -$92.0 million in 2023, then soared by 47.96% to -$47.9 million in 2024, then grew by 26.34% to -$35.3 million in 2025.
  • Its EBT stands at -$35.3 million for Q3 2025, versus -$28.7 million for Q2 2025 and -$43.3 million for Q1 2025.